Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (SHE:002932) — Market Cap & Net Worth
Market Cap & Net Worth: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (SHE:002932) has a market capitalization of $506.29 Million (CN¥3.46 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #12002 globally and #3415 in its home market, demonstrating a 7.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's stock price CN¥14.88 by its total outstanding shares 232520957 (232.52 Million). See Wuhan Easy Diagnosis Biomedicine Co Ltd capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Market Cap History: 2018 to 2026
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's market capitalization history from 2018 to 2026. Data shows growth from $377.41 Million to $506.29 Million (9.13% CAGR).
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.46x
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's market cap is 2.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $377.41 Million | $176.38 Million | $61.42 Million | 2.14x | 6.14x |
| 2019 | $312.13 Million | $181.16 Million | $41.53 Million | 1.72x | 7.52x |
| 2020 | $544.55 Million | $959.10 Million | $468.93 Million | 0.57x | 1.16x |
| 2021 | $933.64 Million | $2.83 Billion | $1.41 Billion | 0.33x | 0.66x |
| 2022 | $1.15 Billion | $10.53 Billion | $4.21 Billion | 0.11x | 0.27x |
| 2023 | $775.33 Million | $749.54 Million | $74.93 Million | 1.03x | 10.35x |
| 2024 | $626.06 Million | $350.06 Million | $74.52 Million | 1.79x | 8.40x |
| 2025 | $652.60 Million | $265.08 Million | -$16.46 Million | 2.46x | N/A |
Competitor Companies of 002932 by Market Capitalization
Companies near Wuhan Easy Diagnosis Biomedicine Co Ltd Class A in the global market cap rankings as of August 4, 2026.
Key companies related to Wuhan Easy Diagnosis Biomedicine Co Ltd Class A by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #113 globally with a market cap of $186.27 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #180 globally with a market cap of $130.57 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #239 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #113 | Abbott Laboratories | NYSE:ABT | $186.27 Billion | $107.12 |
| #180 | Stryker Corporation | NYSE:SYK | $130.57 Billion | $341.20 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #239 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $86.68 |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's market cap moved from $377.41 Million to $ 506.29 Million, with a yearly change of 9.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥506.29 Million | -22.42% |
| 2025 | CN¥652.60 Million | +4.24% |
| 2024 | CN¥626.06 Million | -19.25% |
| 2023 | CN¥775.33 Million | -32.71% |
| 2022 | CN¥1.15 Billion | +23.40% |
| 2021 | CN¥933.64 Million | +71.45% |
| 2020 | CN¥544.55 Million | +74.46% |
| 2019 | CN¥312.13 Million | -17.30% |
| 2018 | CN¥377.41 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $506.29 Million USD |
| MoneyControl | $506.29 Million USD |
| MarketWatch | $506.29 Million USD |
| marketcap.company | $506.29 Million USD |
| Reuters | $506.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more